Inovio Pharmaceuticals Inc
NASDAQ:INO
Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. The company is headquartered in San Diego, California and currently employs 317 full-time employees. The firm is focused on bringing to market designed deoxyribonucleic acid (DNA) medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer, and conditions associated with human papillomavirus (HPV). Its DNA medicines pipeline consists of three types of product candidates, namely prophylactic DNA vaccines, therapeutic DNA immunotherapies, and DNA encoded monoclonal and bispecific antibodies (dMAbs and dBTAs), which utilizes the two components of INOVIO's integrated platform, SynCon and CELLECTRA. The firm's SynCon technology creates optimized plasmids. INOVIO's CELLECTRA smart delivery devices facilitate uptake of its DNA medicines into the cell. Its SynCon DNA medicines are designed to generate antigen-specific antibody and T cell responses.
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. The company is headquartered in San Diego, California and currently employs 317 full-time employees. The firm is focused on bringing to market designed deoxyribonucleic acid (DNA) medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer, and conditions associated with human papillomavirus (HPV). Its DNA medicines pipeline consists of three types of product candidates, namely prophylactic DNA vaccines, therapeutic DNA immunotherapies, and DNA encoded monoclonal and bispecific antibodies (dMAbs and dBTAs), which utilizes the two components of INOVIO's integrated platform, SynCon and CELLECTRA. The firm's SynCon technology creates optimized plasmids. INOVIO's CELLECTRA smart delivery devices facilitate uptake of its DNA medicines into the cell. Its SynCon DNA medicines are designed to generate antigen-specific antibody and T cell responses.
Regulatory Progress: Inovio completed the rolling BLA submission for INO-3107 and expects FDA file acceptance by year-end, with a potential PDUFA date in mid-2026.
Clinical Differentiation: INO-3107 showed a 78% reduction in surgeries over two years and does not require additional surgeries during treatment, differentiating it from Papzimeos.
Commercial Readiness: The company is finalizing launch preparations, including market research, pricing strategy, and building its commercial team to ensure a swift launch upon approval.
Operating Expenses: Operating expenses fell 22% year-over-year to $21.2 million for the quarter, reflecting ongoing cost discipline.
Cash Position: Inovio ended the quarter with $50.8 million in cash, projecting runway into Q2 2026.
Pipeline Updates: Promising proof-of-concept data for the DMAb and DPROT technologies was highlighted, with ongoing work in protein and antibody-based therapies.
